News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial
Sanofi has agreed to shell out an additional $22 million — bringing its total cash investment to $77 million — to expand a discovery pact with Nurix Therapeutics for up to five targeted protein degradation candidates, the companies said Thursday.
The pharma giant and small biotech originally tied up in December 2019, agreeing to pursue three of Nurix’s candidates, which use E3 ligases to selectively target protein receptor sites. That deal came with up to $2.5 billion in future milestones — a figure that stayed the same with Sanofi’s expansion of the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
